Department of Neurology West China Hospital, Sichuan University Chengdu Sichuan China.
J Am Heart Assoc. 2024 Sep 3;13(17):e034829. doi: 10.1161/JAHA.124.034829. Epub 2024 Aug 29.
Endovascular treatment (EVT) has been demonstrated to be effective for patients with tandem occlusion. The efficacy and safety of intravenous thrombolysis before EVT in patients with tandem occlusion remain debatable.
We conducted a systematic review and meta-analysis with PubMed, EMBASE, and the Cochrane Library from inception to September 2023. The primary outcome was functional independence, defined as a modified Rankin Scale score of 0 to 2 at 90 days. The secondary outcomes included the successful recanalization rate, symptomatic intracerebral hemorrhage, and mortality at 90 days. In total, 9 studies with 1838 enrolled participants were identified. Our results showed that, compared with treatment with EVT alone, intravenous thrombolysis before EVT was associated with a greater proportion of functional independence at 90 days (odds ratio [OR], 1.39 [95% CI, 1.14-1.69]; =0.001), a greater rate of successful recanalization (OR, 1.45 [95% CI, 1.11-1.89]; =0.007) and decreased mortality (OR, 0.68 [95% CI, 0.50-0.93]; =0.02). Furthermore, there was no significant difference in symptomatic intracerebral hemorrhage between the intravenous thrombolysis plus EVT group and the EVT alone group (OR, 1.16 [95% CI, 0.79-1.70]; =0.45).
In patients with acute ischemic stroke and tandem occlusion, intravenous thrombolysis before EVT was associated with a greater rate of favorable functional outcomes and successful recanalization and a lower mortality rate without an increased risk of symptomatic intracerebral hemorrhage compared with patients receiving EVT alone.
血管内治疗(EVT)已被证明对串联闭塞患者有效。在串联闭塞患者中,EVT 前静脉溶栓的疗效和安全性仍存在争议。
我们进行了一项系统评价和荟萃分析,检索了PubMed、EMBASE 和 Cochrane Library 从建库到 2023 年 9 月的数据。主要结局为 90 天的功能独立性,定义为改良 Rankin 量表评分为 0-2 分。次要结局包括 90 天的再通率、症状性颅内出血和死亡率。共纳入 9 项研究,共计 1838 名参与者。
与单独 EVT 治疗相比,EVT 前静脉溶栓治疗与 90 天的功能独立性更高相关(优势比 [OR],1.39 [95%置信区间,1.14-1.69];=0.001),再通率更高(OR,1.45 [95%置信区间,1.11-1.89];=0.007)和死亡率降低(OR,0.68 [95%置信区间,0.50-0.93];=0.02)。此外,静脉溶栓联合 EVT 组与单独 EVT 组的症状性颅内出血发生率无显著差异(OR,1.16 [95%置信区间,0.79-1.70];=0.45)。
在急性缺血性脑卒中伴串联闭塞患者中,与单独 EVT 相比,EVT 前静脉溶栓治疗可提高功能结局良好和再通的比例,降低死亡率,且不增加症状性颅内出血的风险。